By Matthew Chance
Moscow (CNN) – Russia intends to be the first in the world to approve a coronavirus vaccine, in less than two weeks, CNN has learned. And despite concerns about its safety, effectiveness and over whether the country has cut essential corners in development, interest in the vaccine has already been expressed by at least 20 countries and some US companies, Russian officials say.
Officials told CNN on Wednesday that they were working toward a date of August 10 or earlier for approval of the vaccine, which has been created by the Moscow-based Gamaleya Institute. It will be approved for public use, with frontline healthcare workers getting it first, they said.
“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union.
“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he added.
But Russia has released no scientific data on its vaccine testing and CNN is unable to verify its claimed safety or effectiveness. Critics say the country’s push for a vaccine comes amid political pressure from the Kremlin, which is keen to portray Russia as a global scientific force.
There are also wide concerns the human testing of the vaccine is incomplete.
Dozens of vaccine trials are underway around the world and a small number are in large-scale efficacy trials, but most developers have cautioned that much work remains before their vaccines can be approved.
Infecting volunteers with Covid-19 might speed up the race for a vaccine. But it could be risky
Infecting volunteers with Covid-19 might speed up the race for a vaccine. But it could be risky
India, Brazil and Saudi Arabia are among dozens of countries that have expressed interest in Russia’s vaccine, according to Russian officials. CNN has reached out to the three named countries but has not received any responses.
And while there hasn’t been a “full official approach to Russia from the US side,” some private companies in the US have also “started preliminary inquiries to find out more about the vaccine,” Dmitriev claimed Thursday. However, the sovereign wealth fund declined to name the companies.
Russia is open to cooperating with the US, according to Dmitriev. He added that he does not “exclude the possibility that the [US] will be one of the countries to approve the Russian vaccine, following clinical trials and approvals.”
While some global vaccines are in the third phase of trials, the Russian vaccine is yet to complete its second phase. Developers plan to complete that phase by August 3, and then conduct the third phase of testing in parallel with the vaccination of the medical workers.
Russians scientists say the vaccine has been quick to develop because it is a modified version of one already created to fight against other diseases. That’s the approach being taken in many other countries and by other companies.
Notably, Moderna, whose vaccine is being backed by the US government and which started Phase 3 testing Monday, has built its coronavirus vaccine on the backbone of a vaccine it had been developing for a related virus, MERS. While this has sped the development process, US and European regulators are requiring the full complement of safety and efficacy tests for the vaccine.
Russia’s defense ministry says that soldiers served as volunteers in human trials.
In recorded comments provided to CNN, Alexander Ginsburg, the director of the project, said he has already injected himself with the vaccine.
Russian officials say the drug is being fast-tracked through approval because of the global pandemic and Russia’s own severe coronavirus problem. The country now has more than 800,000 confirmed cases.
“Our scientists focused not on being the first but on protecting people,” said Dmitriev.
The vaccine uses human adenovirus vectors that have been made weaker so they do not replicate in the body. Unlike most vaccines in development it relies on two vectors, not one, and patients would receive a second booster shot.
Officials say their scientific data is currently being compiled and will be made available for peer review and publication in early August.
“Russia marshaled its leadership position in vaccine development and its proven Ebola and MERS vaccine platform to bring the first safe and efficient solution to the world’s biggest problem,” Dmitriev told CNN previously.
The World Health Organization says there is no approved vaccine for MERS.
Nonetheless, officials from the Russian Direct Investment Fund told CNN at least 20 countries had expressed interest in obtaining the vaccine, including India, Brazil and Saudi Arabia. CNN could not immediately verify these details but has reached out to the countries mentioned for comment.
The Health Ministry says frontline medical staff will be the first vaccinated, once the new drug has been approved for public use.
In a government meeting on Wednesday, Russian Deputy Prime Minister Tatyana Golikova confirmed that the vaccine would be registered in August, while adding Russia would mass-produce it by September.
Large-scale vaccine trials in the United Kingdom, the United States and elsewhere are proceeding rapidly but have not committed to deadlines by which their products will be approved.
Early results from trials of a vaccine developed by the University of Oxford and AstraZeneca were promising, but Mike Ryan, executive director of the World Health Organization Health Emergencies Program, said earlier this month that “there’s a long way to go.”
“These are Phase 1 studies. We now need to move into larger scale real-world trials, but it is good to see more data and more products moving into this very important phase of vaccine discovery,” he said.
Earlier this month, the Kremlin denied allegations Russian spies hacked into American, Canadian and British research labs to steal vaccine development secrets.
Russian officials also denied reports that members of the country’s political and business elite — including Russian President Vladimir Putin — had been given early access to the vaccine.
CNN’s Zahra Ullah contributed to this report from Moscow and Rob Picheta contributed from London.
